Source disclosure: January 22, 2026
Cyfuse Biomedical K.K. [4892.T]
TOKYO — Cyfuse Biomedical K.K. (4892), represented by Chief Executive Officer Akibashi Shizuka, announced today that its board of directors has resolved to grant voting rights to shareholders who acquired new shares after the record date of December 31, 2025, for the upcoming annual general meeting scheduled for late March 2026.
The company will allocate voting rights to Kuraray Co., Ltd., which purchased 352,100 ordinary shares on January 9, 2026, as part of a third-party allotment. This allocation grants Kuraray 3,521 votes, representing approximately 3.53 percent of the total voting rights based on the number of outstanding shares as of December 31, 2025.
Cyfuse Biomedical's decision is rooted in its business and capital alliance agreement with Kuraray Co., Ltd., formalized on December 24, 2025. The rationale behind granting these voting rights aligns with the long-term growth strategy shared between both companies. By reflecting the most recent shareholder sentiment possible without disrupting the preparation for the annual general meeting, the company aims to enhance shareholder engagement, improve corporate governance, and maximize enterprise value.
For more detailed information regarding this third-party allotment, interested parties can refer to the announcement published on December 24, 2025, titled "Notice Regarding Business-Capital Alliance Agreement with Kuraray Co., Ltd. and Issuance of New Shares through Third-Party Allotment."
AI-translated content. 🟢 Confidence: High See terms • Original filing